ERBB2 and breast carcinoma: Although the DESTINY-Break04 study showed that T-DXd significantly prolonged the progression-free survival and overall survival in patients with advanced breast cancer with low HER2 expression [31], the response rate to DS-8201 is limited in colorectal cancer patients with HER2 low expression, as reported by the DESTINY-CRC01 study [32].